Hereditary Transthyretin Amyloidosis with Polyneuropathy
📧 Sign up to get email alerts when something new happens for Hereditary Transthyretin Amyloidosis with Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
A non-interventional observational study sponsored by AstraZeneca to collect data on patients with transthyretin amyloidosis, including ATTR…
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) [Phase 1]
Phase 1 study of NTLA-2001 in hereditary transthyretin amyloidosis with polyneuropathy and transthyretin amyloid cardiomyopathy has complete…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: A Non-interventional Cohort Safety Study of Patients With hATTR-PN
A non-interventional cohort safety study of patients with hereditary transthyretin amyloidosis with polyneuropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients [NA]
This clinical trial is evaluating longitudinal quantitative neuromuscular MRI in patients with neuropathies and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN [Phase 4]
Phase 4 study evaluating adverse events within one day of TEGSEDI administration in adults with hereditary transthyretin amyloidosis with po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.